In this section you will find Therapeutics Line of Treatment Targeted market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities in the biotech, life science and pharmaceutical industries.
Published by TriMark Publications LLC on Jun 1st, 2009
€ 1,339.00
With a unique ability to specifically target diseased cells while leaving healthy cells unaffected, monoclonal antibodies can serve to diagnose and treat a wide range of medical conditions.Learn More
This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.Learn More
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry.Learn More
In this comprehensive report covering targeted therapies in oncology, BioSeeker Group has analyzed apoptopic agents, protein kinase inhibitors, anti-angiogenic and vascular targeting agents, immunostimulators, antibodies and vaccines in oncology.Learn More
This extensive 350+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. Learn More
This extensive 345+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three key oncology areas: Apoptotic agents, Protein Kinase Inhibitors and Anti-Angiogenic agents.Learn More
Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications.Learn More
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Non Small Cell Lung Cancer Therapeutics, Protein Kinase Inhibitors and Anti-angiogenesis and Vascular Targeting in Oncology, which are all subjects to an extensive number of innovative drug candidates.Learn More
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Lymphoma, Protein Kinase Inhibitors and Therapeutic Antibodies, which are all subjects to an extensive number of innovative drug candidates. This extensive 320 pages report compiles and analyzes the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.Learn More
Published by BioSeeker Group (Multi-report (See individual release dates))
€ 7,950.00
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances.Learn More